Recent News

• 12.10.2025 - Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
• 12.09.2025 - Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
• 11.06.2025 - Tim Van
• 11.06.2025 - Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
• 11.06.2025 - Denali Therapeutics Announces Board and Executive Leadership Updates
• 10.13.2025 - Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)

Recent Filings

• 12.09.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 12.04.2025 - 8-K Current report
• 12.04.2025 - EX-99.1 EX-99.1
• 12.04.2025 - EX-99.1 EX-99.1
• 12.04.2025 - 8-K Current report
• 12.04.2025 - 144 Report of proposed sale of securities
• 11.06.2025 - 8-K Current report
• 11.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.06.2025 - EX-99.1 EX-99.1